Literature DB >> 22521851

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies.

Elisa Faenzi1, Luisanna Zedda, Monia Bardelli, Fabiana Spensieri, Erica Borgogni, Gianfranco Volpini, Francesca Buricchi, Franco Laghi Pasini, Pier Leopoldo Capecchi, Fabio Montanaro, Riccardo Belli, Maria Lattanzi, Simona Piccirella, Emanuele Montomoli, Syed Sohail Ahmed, Rino Rappuoli, Giuseppe Del Giudice, Oretta Finco, Flora Castellino, Grazia Galli.   

Abstract

Protective antibody responses to a single dose of 2009 pandemic vaccines have been observed in the majority of healthy subjects aged more than 3 years. These findings suggest that immune memory lymphocytes primed by previous exposure to seasonal influenza antigens are recruited in the response to A/H1N1 pandemic vaccines and allow rapid seroconversion. However, a clear dissection of the immune memory components favoring a fast response to pandemic vaccination is still lacking. Here we report the results from a clinical study where antibody, CD4+ T cell, plasmablast and memory B cell responses to one dose of an MF59-adjuvanted A/H1N1 pandemic vaccine were analyzed in healthy adults. While confirming the rapid appearance of antibodies neutralizing the A/H1N1 pandemic virus, we show here that the response is dominated by IgG-switched antibodies already in the first week after vaccination. In addition, we found that vaccination induces the rapid expansion of pre-existing CD4+ T cells and IgG-memory B lymphocytes cross-reactive to seasonal and pandemic A/H1N1 antigens. These data shed light on the different components of the immune response to the 2009 H1N1 pandemic influenza vaccination and may have implications in the design of vaccination strategies against future influenza pandemics.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22521851     DOI: 10.1016/j.vaccine.2012.04.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  The generation of memory B cells is maintained, but the antibody response is not, in the elderly after repeated influenza immunizations.

Authors:  Daniela Frasca; Alain Diaz; Maria Romero; Bonnie B Blomberg
Journal:  Vaccine       Date:  2016-04-20       Impact factor: 3.641

2.  Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.

Authors:  Donald D Raymond; Shaun M Stewart; Jiwon Lee; Jack Ferdman; Goran Bajic; Khoi T Do; Michael J Ernandes; Pirada Suphaphiphat; Ethan C Settembre; Philip R Dormitzer; Giuseppe Del Giudice; Oretta Finco; Tae Hyun Kang; Gregory C Ippolito; George Georgiou; Thomas B Kepler; Barton F Haynes; M Anthony Moody; Hua-Xin Liao; Aaron G Schmidt; Stephen C Harrison
Journal:  Nat Med       Date:  2016-11-07       Impact factor: 53.440

3.  Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination.

Authors:  Rodrigo B Abreu; Greg A Kirchenbaum; Emily F Clutter; Giuseppe A Sautto; Ted M Ross
Journal:  JCI Insight       Date:  2020-01-16

4.  Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

Authors:  Casey Johnson; Matthew Hohenboken; Terry Poling; Peter Jaehnig; Niranjan Kanesa-Thasan
Journal:  J Infect Dis       Date:  2014-12-23       Impact factor: 5.226

5.  Memory CD4+ T cells enhance B-cell responses to drifting influenza immunization.

Authors:  Emily Gage; Neal Van Hoeven; Natasha Dubois Cauwelaert; Sasha E Larsen; Jesse Erasmus; Mark T Orr; Rhea N Coler
Journal:  Eur J Immunol       Date:  2018-12-21       Impact factor: 5.532

6.  Impact of immunosuppression on recall immune responses to influenza vaccination in stable renal transplant recipients.

Authors:  Michelle Cowan; W James Chon; Amishi Desai; Sarah Andrews; Yaohui Bai; Vic Veguilla; Jacqueline M Katz; Michelle A Josephson; Patrick C Wilson; Roger Sciammas; Anita S Chong
Journal:  Transplantation       Date:  2014-04-27       Impact factor: 4.939

7.  B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination.

Authors:  Mark Y Sangster; Jane Baer; Felix W Santiago; Theresa Fitzgerald; Natalia A Ilyushina; Aarthi Sundararajan; Alicia D Henn; Florian Krammer; Hongmei Yang; Catherine J Luke; Martin S Zand; Peter F Wright; John J Treanor; David J Topham; Kanta Subbarao
Journal:  Clin Vaccine Immunol       Date:  2013-04-10

8.  Safety and immunogenicity of co-administered MF59-adjuvanted 2009 pandemic and plain 2009-10 seasonal influenza vaccines in rheumatoid arthritis patients on biologicals.

Authors:  F Milanetti; V Germano; R Nisini; I Donatelli; A Di Martino; M Facchini; C Ferlito; A Cappella; D Crialesi; S Caporuscio; R Biselli; F Rossi; S Salemi; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

9.  Intra-seasonal antibody repertoire analysis of a subject immunized with an MF59®-adjuvanted pandemic 2009 H1N1 vaccine.

Authors:  Jack Ferdman; Giuseppe Palladino; Hua-Xin Liao; M Anthony Moody; Thomas B Kepler; Giuseppe Del Giudice; Philip R Dormitzer; Stephen C Harrison; Ethan C Settembre; Pirada Suphaphiphat
Journal:  Vaccine       Date:  2018-07-25       Impact factor: 4.169

10.  Ex vivo analysis of human memory B lymphocytes specific for A and B influenza hemagglutinin by polychromatic flow-cytometry.

Authors:  Monia Bardelli; Liliana Alleri; Francesca Angiolini; Francesca Buricchi; Simona Tavarini; Chiara Sammicheli; Sandra Nuti; Elena Degl'Innocenti; Isabelle Isnardi; Elena Fragapane; Giuseppe Del Giudice; Flora Castellino; Grazia Galli
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.